CSL Ltd approaches CEO succession and financial reset

CSL Ltd is navigating a period of leadership transition and financial restructuring. The company has been led by interim CEO Gordon Naylor since February following the retirement of Dr. Paul McKenzie. While the board has described the global search for a permanent successor as “well-advanced,” no official timetable for the appointment has been released.

Financially, CSL is working toward a reset. Recent results showed revenue of US$15.8 billion and an underlying NPATA of US$3.1 billion. The company reported a statutory loss of US$2.6 billion, impacted by US$7.1 billion in pre-tax impairments and US$799 million in restructuring costs. To support shareholders, CSL has announced an A$1.1 billion buyback for FY27 and guides toward underlying profit growth of approximately 5% at constant currency.

Long-term outlooks focus on the CSL Behring division and its plasma-derived therapies. Analysts suggest earnings per share could grow steadily, with forecasts reaching $10.15 by FY29. Additionally, the company is managing the potential demerger of its flu vaccines business, Seqirus, though the timing remains subject to market conditions.